ADVISORY BOARD

Bringing over 35 years of senior leadership experience in the biopharmaceutical industry, Dr. Moreau has held executive positions at Roche, Novartis, Sanofi, Bayer and UCB, where he led enterprise-level strategy, business transformation, and cross-border deals. Prior to joining YolTech, Dr. Moreau served as President of UCB China, overseeing a major restructuring and the divestment of legacy assets through strategic partnerships.

Dr. Moreau holds a Doctorate in Pharmaceutical and Biological Sciences from Rene Descartes University, an MBA from La Sorbonne University in France and graduated from the INSEAD Advanced Management Program and from the General Management Program at Harvard Business School.

Prof. Ott brings more than thirty years of experience in hepatology, gene, and cell therapy, moving early-stage innovations toward clinical application. He currently serves as Professor of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School, where he leads the Center for Gene and Cell Therapy of Liver Diseases. His additional leadership roles include principal investigator at TWINCORE – Center for Experimental and Clinical Infection Research, and senior investigator at the REBIRTH Center for Translational Regenerative Medicine.

Prof. Ott’s pioneering work in liver gene therapy, base editing, and organoid engineering has yielded more than 200 peer-reviewed publications. His research has appeared in leading journals including Cell, Cell Stem Cell, Nature Communications, Gastroenterology, Gut, Journal of Hepatology, and Hepatology, with over 9,000 citations to date and an H-index of 48.